Skip to main content

GD2CART for Osteosarcoma or Neuroblastoma

GD2CART for Osteosarcoma or Neuroblastoma

Contact

If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is now recruiting. Learn more about enrolling here.

Description

This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory). This study involves an investigational cellular therapy called GD2CART. The study will be testing different doses of the study drug to find the safest dose.

What to expect

Participants in this research will:
  • Have an electrocardiogram (ECG) and echocardiogram (ECHO) before receiving the cellular therapy
  • Undergo apheresis to remove white blood cells (called T Cells) from their blood
  • Receive the cellular therapy called GD2CART via infusion. This is manufactured from participant's T Cells.
  • Complete frequent clinic visits at CHOP
  • Have research blood tests
  • Have extra or leftover tissue collected if they have a biopsy as part of regular cancer care

Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.

Jump back to top